A new DDW 2025 study reveals a surprising truth: most post-polypectomy colorectal cancers are diagnosed before recommended follow-up—and many are already advanced. So, what’s driving these missed opportunities? The quality of the baseline colonoscopy is under scrutiny, with evidence pointing to missed or incompletely resected lesions and significant differences in cancer risk tied to a physician’s adenoma detection rate (ADR). As concerns grow around patient compliance and procedural performance, could noninvasive tools like FIT help close the gap in surveillance? The case for rethinking traditional CRC monitoring is growing.
Author: Abhay Panchal
In a compelling new article, Dr. John Halamka and Paul Cerrato unpack how natural language processing (NLP) is transforming healthcare—turning complex human communication into data machines can analyze, learn from, and act on. From summarizing dense health records to powering ChatGPT, NLP’s blend of computational linguistics and deep learning is quietly reshaping how medicine interacts with technology. But how exactly do machines interpret figurative phrases or reorder grammar across languages? The answer lies in the science of transformers and self-attention—and it’s more intuitive than you might think.
From value-based care to contract renegotiations and patient education, four GI leaders shared with Becker’s how they’re adapting to a shifting payer landscape — and what they’re preparing for next.
Medtronic is spinning off its Diabetes business into a new standalone company—creating waves across the healthcare tech landscape. The move, announced on May 21, 2025, aims to sharpen Medtronic’s focus on high-margin growth areas like robotics, neuromodulation, and cardiovascular innovation. The New Diabetes Company will emerge as the only scaled player with a fully integrated insulin management ecosystem, uniquely positioned for direct-to-consumer leadership. With over 8,000 employees and global reach, the spinout will also free up capital and increase Medtronic’s earnings potential. Why is Medtronic shedding a core business now? The answer may redefine the next chapter of digital chronic…
With 19 million more patients now eligible for colorectal cancer screening, the gastroenterology workforce is under mounting pressure—and private practices are at a breaking point. At DDW 2025, Dr. Asma Khapra warned that the percentage of fully independent GI practices has plunged from 30% to just 13% since 2019. As burnout, administrative burden, and staffing costs rise, private practices must rethink how they retain talent. Khapra offered a compelling strategy centered on the “Iceberg Model of Culture,” urging leaders to focus not just on visible perks, but on invisible elements like trust, fairness, and physician autonomy. Without action, the future…
Imec, in partnership with OnePlanet Research Center, introduced a highly miniaturized ingestible sensor for real-time gut health monitoring. Demonstrated live at ITF World 2025, the sensor is three times smaller than conventional capsule endoscopies and is the first to measure redox balance—an indicator of oxidative stress and inflammation—along with pH and temperature throughout the gastrointestinal tract. The device, just 2.1 cm long and 0.75 cm in diameter, offers a non-invasive alternative to traditional endoscopy and colonoscopy, which can be uncomfortable and limited in scope.
This wasn’t just a talk. It was a line in the sand. What if we’re solving the wrong problem in GI?What if the real question isn’t how efficiently we scope……but whether we should be doing them at all—at the scale we do today? At the AGA Tech Summit in Chicago, I posed a challenge: The future isn’t coming. It’s already here. And what happens in 2035 depends entirely on the actions we take—or avoid—today. GI is at a BIG inflection point. Most won’t realize until it’s already passed them by. There’s no rewinding this.This keynote is about more than technology. It’s about…
In a wide-ranging interview, Prof. Alexander Hann of the University Hospital Würzburg shared that while AI has improved adenoma detection rates in colonoscopies, the expected real-world impact—like reduced mortality—remains statistically insignificant. Despite over 40 randomized trials, the evidence has not led to widespread guideline endorsement. Concerns around over-reliance on AI, false positives, and “de-skilling” persist. Hann stresses that for AI to truly transform GI care, interdisciplinary research, robust multi-center datasets, and better endpoints are key.
Despite ranking as the fifth highest-paid specialty, many gastroenterologists report some of the lowest job satisfaction in medicine. According to a new report by Marit Health, stagnant wages—when adjusted for inflation—combined with CMS cuts and private equity consolidation are eroding compensation and autonomy in the field.
The upcoming IPOs of Hinge Health and Omada Health are more than capital events—they may mark a turning point for HealthTech M&A. According to Nelson Advisors, these high-profile debuts are poised to reset investor sentiment, validate virtual care models, and push up acquisition multiples for digital health companies. If the market rewards these IPOs, expect a ripple effect: rising benchmarks, faster deal activity, and renewed urgency among buyers who don’t want to miss the next breakout.